158 related articles for article (PubMed ID: 8709110)
1. Bis tertiary amide inhibitors of the HIV-1 protease generated via protein structure-based iterative design.
Melnick M; Reich SH; Lewis KK; Mitchell LJ; Nguyen D; Trippe AJ; Dawson H; Davies JF; Appelt K; Wu BW; Musick L; Gehlhaar DK; Webber S; Shetty B; Kosa M; Kahil D; Andrada D
J Med Chem; 1996 Jul; 39(14):2795-811. PubMed ID: 8709110
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide series.
Reich SH; Melnick M; Pino MJ; Fuhry MA; Trippe AJ; Appelt K; Davies JF; Wu BW; Musick L
J Med Chem; 1996 Jul; 39(14):2781-94. PubMed ID: 8709109
[TBL] [Abstract][Full Text] [Related]
3. Potent human immunodeficiency virus type 1 protease inhibitors that utilize noncoded D-amino acids as P2/P3 ligands.
Jungheim LN; Shepherd TA; Baxter AJ; Burgess J; Hatch SD; Lubbehusen P; Wiskerchen M; Muesing MA
J Med Chem; 1996 Jan; 39(1):96-108. PubMed ID: 8568831
[TBL] [Abstract][Full Text] [Related]
4. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease.
Kaldor SW; Kalish VJ; Davies JF; Shetty BV; Fritz JE; Appelt K; Burgess JA; Campanale KM; Chirgadze NY; Clawson DK; Dressman BA; Hatch SD; Khalil DA; Kosa MB; Lubbehusen PP; Muesing MA; Patick AK; Reich SH; Su KS; Tatlock JH
J Med Chem; 1997 Nov; 40(24):3979-85. PubMed ID: 9397180
[TBL] [Abstract][Full Text] [Related]
5. A new structural theme in C2-symmetric HIV-1 protease inhibitors: ortho-substituted P1/P1' side chains.
Wannberg J; Sabnis YA; Vrang L; Samuelsson B; Karlén A; Hallberg A; Larhed M
Bioorg Med Chem; 2006 Aug; 14(15):5303-15. PubMed ID: 16621572
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.
Thaisrivongs S; Janakiraman MN; Chong KT; Tomich PK; Dolak LA; Turner SR; Strohbach JW; Lynn JC; Horng MM; Hinshaw RR; Watenpaugh KD
J Med Chem; 1996 Jun; 39(12):2400-10. PubMed ID: 8691434
[TBL] [Abstract][Full Text] [Related]
7. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
[TBL] [Abstract][Full Text] [Related]
8. Aza-peptide analogs as potent human immunodeficiency virus type-1 protease inhibitors with oral bioavailability.
Fässler A; Bold G; Capraro HG; Cozens R; Mestan J; Poncioni B; Rösel J; Tintelnot-Blomley M; Lang M
J Med Chem; 1996 Aug; 39(16):3203-16. PubMed ID: 8759643
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.
Mahalingam AK; Axelsson L; Ekegren JK; Wannberg J; Kihlström J; Unge T; Wallberg H; Samuelsson B; Larhed M; Hallberg A
J Med Chem; 2010 Jan; 53(2):607-15. PubMed ID: 19961222
[TBL] [Abstract][Full Text] [Related]
10. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
Mimoto T; Nojima S; Terashima K; Takaku H; Shintani M; Hayashi H
Bioorg Med Chem; 2008 Feb; 16(3):1299-308. PubMed ID: 17981045
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.
Skulnick HI; Johnson PD; Aristoff PA; Morris JK; Lovasz KD; Howe WJ; Watenpaugh KD; Janakiraman MN; Anderson DJ; Reischer RJ; Schwartz TM; Banitt LS; Tomich PK; Lynn JC; Horng MM; Chong KT; Hinshaw RR; Dolak LA; Seest EP; Schwende FJ; Rush BD; Howard GM; Toth LN; Wilkinson KR; Romines KR
J Med Chem; 1997 Mar; 40(7):1149-64. PubMed ID: 9089336
[TBL] [Abstract][Full Text] [Related]
13. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
[TBL] [Abstract][Full Text] [Related]
14. Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors.
De Lucca GV; Liang J; De Lucca I
J Med Chem; 1999 Jan; 42(1):135-52. PubMed ID: 9888839
[TBL] [Abstract][Full Text] [Related]
15. Potent and selective inhibitors of human immunodeficiency virus protease structurally related to L-694,746.
Franchetti P; Perlini P; Abu Sheikha G; Cappellacci L; Grifantini M; Loi AG; De Montis A; Pani A; Marongiu ME; La Colla P
Antivir Chem Chemother; 1998 Jul; 9(4):303-9. PubMed ID: 9875409
[TBL] [Abstract][Full Text] [Related]
16. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of potent HIV-1 protease inhibitors incorporating hydroxyprolinamides as novel P2 ligands.
Gao BL; Zhang CM; Yin YZ; Tang LQ; Liu ZP
Bioorg Med Chem Lett; 2011 Jun; 21(12):3730-3. PubMed ID: 21555220
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.
Alterman M; Björsne M; Mühlman A; Classon B; Kvarnström I; Danielson H; Markgren PO; Nillroth U; Unge T; Hallberg A; Samuelsson B
J Med Chem; 1998 Sep; 41(20):3782-92. PubMed ID: 9748353
[TBL] [Abstract][Full Text] [Related]
19. Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.
Nugiel DA; Jacobs K; Cornelius L; Chang CH; Jadhav PK; Holler ER; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Logue KA; Gorey-Feret LJ; Lam GN; Erickson-Viitanen S; Seitz SP
J Med Chem; 1997 May; 40(10):1465-74. PubMed ID: 9154969
[TBL] [Abstract][Full Text] [Related]
20. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
